Roridin E
目录号 : KCM11924 CAS No. : 16891-85-3 纯度 : ≥95%
Roridin E is a macrocyclic trichothecene mycotoxin that has been found in M. verrucaria. It inhibits the receptor tyrosine kinases FGFR3, IGF-1R, PDGFRβ, and TrkB (ICs = 0.4, 0.4, 1.4, and 1 μM, respectively). Roridin E induces cytotoxicity in multiple breast cancer cell lines (ICs = 0.02-0.05 nM) and inhibits proliferation in a panel of additional cancer cell lines (ICs = P. falciparum (EC = 0.15 ng/ml), induces phytotoxicity in duckweed and kudzu, and is toxic to mice (LD = 10 mg/kg, i.p.). Roridin E is also produced by the plant B. coridifolia, which is associated with livestock poisoning in South America.
规格 价格 是否有货 数量
500μg
In-stock
1mg
In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Roridin E is a glucose-6-phosphatase (G6Pase) inhibitor and antibiotic, and is a metabolic byproduct of Roridin A . Roridin E induces significant oxidative stress, characterized by depletion of glutathione in vivo, induction of hepatic lipid peroxidation, and inhibition of renal superoxide dismutase activity. Roridin E reduces blood glucose levels in rats, but exhibits acute toxicity (which is enhanced when co-administered with linoleic acid) and causes hepatotoxicity in male albino mice. Roridin E induces a decrease in total blood protein and increases in the levels of total lipids, γ-glutamyltransferase, alkaline phosphatase, and 5'-nucleotidase. Roridin E can be isolated from molds, and possesses cytostatic and antifungal activities similar to those of Verrucarin A and Roridin A. Roridin E exhibits in vivo activity in rodents and is commonly used in hepatotoxicity-related studies.

体内研究

Roridin E (2 mg/kg; subcutaneous injection; Single administration can significantly increase liver glucose-6-phosphatase activity and kidney glutathione levels in male Sprague Dawley rats, while other detected serum, liver, or kidney biochemical parameters show no significant changes.
Roridin E (2 mg/kg; intraperitoneal injection; Single dose administration can induce significant liver toxicity in male albino mice, which can be confirmed by elevated liver oxidative stress markers and changes in serum liver function parameters.

 

Animal Model: Sprague-Dawley (male, 150-170 g)
Dosage: 2 mg/kg
Administration: s.c.; single dose
Result: Showed no significant changes in levels of TBARS, total lipids, glucose, glutathione, creatinine, zinc, or calcium in serum compared to controls.
Increased liver glucose-6-phosphatase activity to 10.6 nmol/min/mg proteins, with no significant changes in TBARS, total lipid, glutathione, 5-nucleotidase, or superoxide dismutase levels in liver compared to controls.
Increased kidney glutathione level to 6.76 μg/mg proteins, with no significant changes in TBARS, total lipid, 5-nucleotidase, glucose-6-phosphatase, or superoxide dismutase levels in kidney compared to controls.
Animal Model: albino mice (male, 6 weeks old, 20-25 g)
Dosage: 2 mg/kg
Administration: i.p.; single dose
Result:
Increased liver tissue TBARs to 2.3 mmol/mL.
Increased liver tissue SOD to 1.9 ng/mL.
Increased liver tissue GSH to 2.9 mmol/mL.
Decreased blood serum total protein to 4.4 g/dl.
Increased blood serum total lipids to 5.8 mg/mL.
Increased blood serum GGT to 32.1 u/mL.
Increased blood serum alkaline phosphatase to 116 u/L.
Increased blood serum 5'-nucleotidase to 1.8 u/mL.
 
分子式
C29H38O8
分子量
514.61
CAS号
16891-85-3
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
  -20°C 1 month
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

配置后的溶液总体积:

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。